Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
Bio Pharma Dive
JUNE 12, 2024
Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.
Let's personalize your content